Norman Schwartz - Bio Rad Chairman
| BIO Stock | USD 338.48 0.75 0.22% |
Chairman
Mr. Norman D. Schwartz is Chairman of the Board, President, Chief Executive Officer of the Company. Mr. Schwartz was our President and Chief Executive Officer since 2003 and our Chairman of the Board since 2012. He was our Vice President from 1989 to 2002, our Group Manager, Life Science, from 1997 to 2002 and our Group Manager, Clinical Diagnostics, from 1993 to 1997. We believe Mr. Schwartzs financial and business expertise gained through over 42 years of service with our Company, including as our President and Chief Executive Officer for over 16 years, give him the qualifications and skills to serve as a director. since 2012.
| Age | 74 |
| Tenure | 12 years |
| Address | 1000 Alfred Nobel Drive, Hercules, CA, United States, 94547 |
| Phone | 510 724 7000 |
| Web | https://www.bio-rad.com |
Bio Rad Management Efficiency
The company has Return on Asset of 0.0186 % which means that on every $100 spent on assets, it made $0.0186 of profit. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of (0.0979) %, meaning that it generated no profit with money invested by stockholders. Bio Rad's management efficiency ratios could be used to measure how well Bio Rad manages its routine affairs as well as how well it operates its assets and liabilities. As of the 28th of November 2024, Return On Tangible Assets is likely to grow to -0.05. In addition to that, Return On Capital Employed is likely to drop to 0.03. At this time, Bio Rad's Total Assets are very stable compared to the past year. As of the 28th of November 2024, Non Current Assets Total is likely to grow to about 9.7 B, while Other Current Assets are likely to drop about 92.3 M.Similar Executives
| Found 14 records | CHAIRMAN Age | ||
| Marilyn Nelson | Inspire Medical Systems | 81 | |
| William Doyle | Novocure | 62 | |
| Frank Laukien | Bruker | 64 | |
| Mark Tryniski | CONMED | 60 | |
| Thomas Burns | Glaukos Corp | 63 | |
| Adam JD | Penumbra | 62 | |
| Bill Sanford | Integer Holdings Corp | 76 | |
| Curt Hartman | CONMED | 60 | |
| Mohsen Sohi | STERIS plc | 61 | |
| David Paul | Globus Medical | 57 | |
| Larry Glasscock | Zimmer Biomet Holdings | 71 | |
| William Link | Glaukos Corp | 74 | |
| Adam Elsesser | Penumbra | 62 | |
| Bryan Hanson | Zimmer Biomet Holdings | 57 | |
Management Performance
| Return On Equity | -0.0979 | ||||
| Return On Asset | 0.0186 |
Bio Rad Laboratories Leadership Team
Elected by the shareholders, the Bio Rad's board of directors comprises two types of representatives: Bio Rad inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Bio. The board's role is to monitor Bio Rad's management team and ensure that shareholders' interests are well served. Bio Rad's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Bio Rad's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Ajit Ramalingam, Senior Vice President Chief Accounting Officer | ||
| Jeffrey Edwards, Independent Director | ||
| Roop CPA, Executive CFO | ||
| Lee Boyd, Senior Pacific | ||
| Courtney Enloe, General VP | ||
| Andrew Last, Chief Operating Officer, Executive Vice President | ||
| Yong Chung, Vice Relations | ||
| Jonathan DiVincenzo, President COO | ||
| Tania DeVilliers, Corporate Director | ||
| Arnold Pinkston, Independent Director | ||
| Timothy Ernst, Executive Vice President General Counsel and Secretary | ||
| Ronald Hutton, Vice President Treasurer | ||
| Jim Barry, Senior Manufacturing | ||
| Alice Schwartz, Director | ||
| Gregory Hinckley, Lead Independent Director | ||
| Kurt DeLanghe, Middle Europe | ||
| Michael Crowley, Executive Vice President - Global Commercial Operations | ||
| Simon May, Executive Vice President and Presidentident - Life Science Group | ||
| Melinda Litherland, Independent Director | ||
| Annette Tumolo, Executive Vice President and Presidentident, Life Science Group | ||
| Dara Wright, Executive Vice President and President of the Clinical Diagnostics Group | ||
| Norman Schwartz, Chairman of the Board, President, Chief Executive Officer | ||
| Ilan Daskal, Chief Financial Officer, Executive Vice President | ||
| Matthew Werner, Senior Officer | ||
| Colleen Corey, Executive Resources | ||
| Roop Lakkaraju, Executive CFO | ||
| Giovanni Magni, Executive Vice President, Chief Strategy Officer | ||
| James Barry, Executive Group |
Bio Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Bio Rad a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.0979 | ||||
| Return On Asset | 0.0186 | ||||
| Profit Margin | (0.30) % | ||||
| Operating Margin | 0.1 % | ||||
| Current Valuation | 9.23 B | ||||
| Shares Outstanding | 22.92 M | ||||
| Shares Owned By Insiders | 15.57 % | ||||
| Shares Owned By Institutions | 79.90 % | ||||
| Number Of Shares Shorted | 524.44 K | ||||
| Price To Earning | 2.90 X |
Pair Trading with Bio Rad
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Bio Rad position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Bio Rad will appreciate offsetting losses from the drop in the long position's value.Moving against Bio Stock
| 0.41 | FDMT | 4D Molecular Therapeutics | PairCorr |
| 0.4 | ICU | LMF Acquisition Oppo | PairCorr |
| 0.36 | MRK | Merck Company Fiscal Year End 6th of February 2025 | PairCorr |
| 0.33 | JNJ | Johnson Johnson Fiscal Year End 28th of January 2025 | PairCorr |
The ability to find closely correlated positions to Bio Rad could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Bio Rad when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Bio Rad - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Bio Rad Laboratories to buy it.
The correlation of Bio Rad is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Bio Rad moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Bio Rad Laboratories moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Bio Rad can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Bio Rad Laboratories. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product. You can also try the Money Flow Index module to determine momentum by analyzing Money Flow Index and other technical indicators.
Is Life Sciences Tools & Services space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Bio Rad. If investors know Bio will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Bio Rad listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 5.412 | Earnings Share (28.09) | Revenue Per Share 90.815 | Quarterly Revenue Growth 0.028 | Return On Assets 0.0186 |
The market value of Bio Rad Laboratories is measured differently than its book value, which is the value of Bio that is recorded on the company's balance sheet. Investors also form their own opinion of Bio Rad's value that differs from its market value or its book value, called intrinsic value, which is Bio Rad's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Bio Rad's market value can be influenced by many factors that don't directly affect Bio Rad's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Bio Rad's value and its price as these two are different measures arrived at by different means. Investors typically determine if Bio Rad is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Bio Rad's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.